Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

Simple Summary Multiple myeloma, a cancer of the bone marrow, is the commonest cancer
of adults in the Western World. Therapies have advanced dramatically in recent years …

Various T-cell redirecting BsAbs are in advanced stages of clinical development with
promising activity and a manageable toxicity profile. Ongoing studies are evaluating …

Ichnos has developed a multi-specific antibody platform based on the BEAT®(Bispecific
engagement by antibodies based on the T-cell receptor) interface. The increased complexity …

Recent therapeutic advances have significantly improved the outcome for patients with
multiple myeloma (MM). The backbone of successful standard therapy is the combination of …

Over the past 30 years the incorporation of monoclonal antibody (mAb) treatments into the
management of hematologic malignancies has led to significant improvements in patient …

The identification and targeting of B cell maturation antigen (BCMA) through
immunotherapeutic strategies such as antibody-drug conjugates (ADC), chimeric antigen …

Off-the-shelf T-cell-redirecting bispecific antibodies targeting BCMA, GPRC5D, and FcRH5
have high activity in multiple myeloma with a manageable toxicity profile. However, not all …

Despite significant clinical benefit achieved by targeted immunotherapies in recent years,
durable responses are still limited in multiple myeloma (MM) 1, 2 potentially due to …

Background: Effective novel therapies for multiple myeloma (MM) patients who are
unresponsive to conventional treatments (triple-class refractory) are an urgent need …